Initial evaluation of safety and efficiency of Kovir hard capsules in the combination regimen with background treatment in patients with mild COVID-19

Abstract

KOVIR hard capsules, developed from a herbal traditional formulation RenShenBaiDuSan. It commonly has been used in respiratory infection treatment. This study was to conducted to investigate the efficacy and safety of using KOVIR hard capsules through the following endpoints: daily viral load, change in TCD4 and TCD8 counts, time to symptom resolution, and daily symptom score, and progression to severe/critical COVID-19. 66 patients with mild COVID-19 aged from 18 to 65 years were recruited and randomized to either KOVIR or placebo for up to 14 days or until discharge. Results showed that the viral loading was similar in both groups. KOVIR group had a more rapid decrease in symptom score and significantly lower time to symptom resolution than the placebo (median: 4 versus 7 days). Two patients (6,25%) in the placebo group developed severe COVID-19. No adverse event had been reported. Conclusion: Preliminary study results suggest that KOVIR was safe and improved symptom resolution in mild COVID-19 patients.